Global NewsHigh Priority (9/10)

New COVID-19 Variant BA.3.2 'Cicada' Spreading Globally

A newly designated COVID-19 variant called BA.3.2, nicknamed 'Cicada,' is rapidly spreading across at least 23 countries and may evade antibodies from current 2025-2026 vaccines, though early data shows no increase in disease severity.

Key Points

  • BA.3.2 'Cicada' variant spreading in 23 countries as of February 2026
  • Variant evades antibodies from current 2025-2026 vaccine formulation
  • No evidence currently of increased disease severity
  • Significant disease burden remains: 390,000-550,000 hospitalizations and 45,000-64,000 deaths in 2024-25 season

Full Details

A new COVID-19 variant designated BA.3.2, nicknamed 'Cicada' due to its timing and pattern of emergence, is spreading rapidly with confirmed presence in 23 countries as of February 2026, according to CDC weekly assessments. While the variant's mutations appear to help it spread more efficiently, there is currently no evidence that BA.3.2 causes more severe disease than the variants circulating during the 2025-2026 winter season. Laboratory studies indicate that the newly emerged variant efficiently evades antibodies from the current 2025-2026 vaccine formulation, likely due to spike-protein mutations. The CDC noted that despite lower rates of severe outcomes in recent years due to widespread infection- and vaccine-derived immunity, the burden remains substantial with an estimated 390,000-550,000 hospitalizations and 45,000-64,000 deaths occurring in the U.S. during the 2024-25 respiratory virus season.

Why It Matters

The variant's ability to evade current vaccine-induced immunity underscores the need for continued variant surveillance and potentially updated vaccine formulations, while the lack of increased severity suggests existing population immunity may still provide meaningful protection against serious outcomes.

Sourcejpost.com

Get stories like this delivered daily

AI-curated news, personalized to your interests. Zero noise.

Start 7-Day Free Trial →

More in Global News